Abstract

Background: The New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial is a randomized phase-III trial comparing rivaroxaban versus aspirin in patients with recent ESUS. Aims: We aimed to describe the baseline characteristics of this large ESUS cohort to explore relationships among key subgroups. Methods: We enrolled 7213 patients at 459 sites in 31 countries. Prespecified subgroups for primary safety and efficacy analyses included age, sex, race, global region, stroke or transient ischemic attack prior to qualifying event, time to randomization, hypertension, and diabetes mellitus. Results: Mean age was 66.9 ± 9.8 years; 24% were under 60 years. Older patients had more hypertension, coronary disease, and cancer. Strokes in older subjects were more frequently cortical and accompanied by radiographic evidence of prior infarction. Women comprised 38% of participants and were older than men. Patients from East Asia were oldest whereas those from Latin America were youngest. Patients in the Americas more frequently were on aspirin prior to the qualifying stroke. Acute cortical infarction was more common in the United States, Canada, and Western Europe, whereas prior radiographic infarctions were most common in East Asia. Approximately forty-five percent of subjects were enrolled within 30 days of the qualifying stroke, with earliest enrollments in Asia and Eastern Europe. Conclusions: NAVIGATE-ESUS is the largest randomized trial comparing antithrombotic strategies for secondary stroke prevention in patients with ESUS. The study population encompasses a broad array of patients across multiple continents and these subgroups provide ample opportunities for future research.

Original languageEnglish
Pages (from-to)1673-1682
Number of pages10
JournalJournal of Stroke and Cerebrovascular Diseases
Volume27
Issue number6
DOIs
StatePublished - Jun 2018
Externally publishedYes

Funding

FundersFunder number
Canadian Stroke Prevention Intervention Network
National Heart, Lung, and Blood InstituteK23HL127227
Janssen Research and Development

    Keywords

    • Embolic Stroke of Undetermined Source (ESUS)
    • Stroke
    • aspirin
    • cerebral embolism
    • cryptogenic stroke
    • randomized trial
    • rivaroxaban
    • stroke prevention

    Fingerprint

    Dive into the research topics of 'Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial'. Together they form a unique fingerprint.

    Cite this